Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

20 Sep 2005 09:13

ReNeuron Group plc20 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS Please note this replaces the announcement made 13:01, 16 September 2005 underRNS number 3827R. The only material change to the body of the text being thedeletion of the holding of Mr M. Hunt, which had been appropriately disclosed inRNS announcement 3838R. This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and PAUL HARPER identify the connected person TREVOR JONES 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised DURING THE 10 YEAR PERIOD FOLLOWING GRANT, SUBJECT TO VESTING AND PERFORMANCE CONDIDTIONS 6 SEPTEMBER 2005 (FOR EACH) 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) PAUL HARPER 50,000 ORDINARY SHARES TREVOR JONES 50,000 ORDINARY SHARES NIL 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise PAUL HARPER: 50,000 OPTIONS TREVOR JONES: 150,000 OPTIONS £0.25 PER SHARE 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 NON EXECUTIVE FLOTATION OPTIONS GRANTED UNDER THE COMPANY'S NON EXECUTIVE SHARE MICHAEL HUNT RENEURON 01483 302 560 OPTION SCHEME Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 201711:30 amRNSNotification of Interim Results
8th Nov 20177:00 amRNSRetinal disease clinical trial moves into Phase II
31st Oct 20177:00 amRNSPositive stroke clinical data & regulatory update
27th Oct 20177:00 amRNSWins further UK grant
11th Oct 20171:31 pmRNSPDMR Interest in Shares and Share Options
9th Oct 20177:00 amRNSPresentation of positive pre-clinical data
12th Sep 20177:00 amRNSDirectors' Interest in Shares and Share Options
6th Sep 201711:15 amRNSResult of AGM
6th Sep 20177:00 amRNSAGM Trading Update
1st Sep 20177:00 amRNSNon-executive Director Appointment
1st Sep 20177:00 amRNSBlock Listing Review and TVR
7th Aug 20173:04 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20174:40 pmRNSSecond Price Monitoring Extn
4th Aug 20174:35 pmRNSPrice Monitoring Extension
25th Jul 20177:00 amRNSAppointment of joint broker
19th Jul 20177:00 amRNSBoard change
29th Jun 20177:00 amRNSPreliminary Results
19th Jun 20177:00 amRNSFDA approves cryopreserved hRPC formulation
8th Jun 20177:00 amRNSNotification of Preliminary Results
5th Jun 20177:00 amRNSPositive FDA feedback on proposed Phase III study
18th May 20177:00 amRNSPresents positive exosome data at major conference
11th May 20177:00 amRNSAwarded major UK cell therapy manufacturing grant
5th May 20177:00 amRNSPresents new exosome data at major conference
21st Apr 20177:01 amRNSUpdate on clinical strategy in stroke disability
21st Apr 20177:00 amRNSUpdate on progress in ophthalmology programmes
1st Mar 20177:00 amRNSBlock Listing Review and Total Voting Rights
15th Feb 20177:00 amRNSReNeuron featured in BBC documentary
7th Feb 201712:32 pmRNSDirector Share Purchase
14th Dec 201612:15 pmRNSDirector Share Purchase
5th Dec 20167:00 amRNSInterim Results
5th Dec 20167:00 amRNSReports Positive Results in Phase II Stroke Trial
14th Nov 20167:00 amRNSNotification of Interim Results
5th Oct 20162:30 pmRNSNotification of Major Interest in Shares
22nd Sep 20161:00 pmRNSBlock Listing Review and Total Voting Rights
6th Sep 201612:00 pmRNSResult of AGM
6th Sep 20167:00 amRNSAGM Trading Update
5th Aug 20164:35 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20167:00 amRNSStroke clinical data published in The Lancet
22nd Jul 20167:00 amRNSPublication of positive pre-clinical retinal data
20th Jul 20162:31 pmRNSDirectors' Interest in Shares and Share Options
7th Jul 20167:00 amRNSPreliminary Results
14th Jun 20167:00 amRNSNotification of Preliminary Results
13th Jun 20167:00 amRNSPatient recruitment completed in stroke trial
9th Jun 20167:01 amRNSPursues brain cancer with exosome platform
8th Jun 20167:00 amRNSRetinitis pigmentosa update & Notice of KOL event
31st May 201612:45 pmRNSChange of Adviser
15th Mar 20167:00 amRNSFirst Patient Treated in RP Clinical Trial
23rd Feb 20167:00 amRNSReNeuron Relocates to South Wales
17th Feb 20164:57 pmRNSDirector's Dealings
3rd Feb 201610:07 amRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.